Literature DB >> 15213806

Preparation of endotoxin-free bacteriophages.

Janusz Boratyński1, Danuta Syper, Beata Weber-Dabrowska, Marzanna Łusiak-Szelachowska, Gryzelda Poźniak, Andrzej Górski.   

Abstract

Bacteriophages (phages) are bacterial viruses that interact with bacterial walls and invade bacterial cells. Moreover, they disturb bacterial metabolism and lead to bacteria lysis. In the case of Gram-negative bacteria crude phage cultures, apart from the phages themselves, the bacterial debris, bacterial proteins and nucleic acids contain endotoxins. These endotoxins (lipopolysaccharides) posses a high degree of toxicity in vitro and in vivo, and their removal is essential for safety in antibacterial bacteriophage therapy. An effective, scaleable purification of bacteriophages from endotoxins was accomplished by sequential ultrafiltration through polysulfone membrane (30 nm) followed by chromatography on sepharose 4B and Matrex Cellulofine Sulfate. The phage fraction after gel filtration chromatography routinely contained endotoxins in the 150-2500 EU/ml range. The procedure yielded bacteriophages contaminated with as little as 0.4-7 EU/ml (Limulus assay). This value lies within the permitted level for intravenous applications (5 EU/kg/h by European Pharmacopoeia, 1997).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213806

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  36 in total

1.  Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy.

Authors:  Timothy K Lu; James J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

2.  Molecular imaging of T4 phage in mammalian tissues and cells.

Authors:  Zuzanna Kaźmierczak; Agnieszka Piotrowicz; Barbara Owczarek; Katarzyna Hodyra; Paulina Miernikiewicz; Dorota Lecion; Marek Harhala; Andrzej Górski; Krystyna Dąbrowska
Journal:  Bacteriophage       Date:  2014-02-27

Review 3.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

4.  Immunogenicity studies of proteins forming the T4 phage head surface.

Authors:  Krystyna Dąbrowska; Paulina Miernikiewicz; Agnieszka Piotrowicz; Katarzyna Hodyra; Barbara Owczarek; Dorota Lecion; Zuzanna Kaźmierczak; Andrey Letarov; Andrzej Górski
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

5.  Standardized bacteriophage purification for personalized phage therapy.

Authors:  Tiffany Luong; Ann-Charlott Salabarria; Robert A Edwards; Dwayne R Roach
Journal:  Nat Protoc       Date:  2020-07-24       Impact factor: 13.491

6.  Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.

Authors:  Diana D Semler; Amanda D Goudie; Warren H Finlay; Jonathan J Dennis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

7.  Effects of bacteriophages on free radical production and phagocytic functions.

Authors:  Anna Przerwa; Michał Zimecki; Kinga Switała-Jeleń; Krystyna Dabrowska; Ewa Krawczyk; Mirosław Łuczak; Beata Weber-Dabrowska; Danuta Syper; Ryszard Miedzybrodzki; Andrzej Górski
Journal:  Med Microbiol Immunol       Date:  2006-01-31       Impact factor: 3.402

8.  Dispersing biofilms with engineered enzymatic bacteriophage.

Authors:  Timothy K Lu; James J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-25       Impact factor: 11.205

9.  The effect of bacteriophages T4 and HAP1 on in vitro melanoma migration.

Authors:  Krystyna Dabrowska; Grzegorz Skaradziński; Paulina Jończyk; Aneta Kurzepa; Joanna Wietrzyk; Barbara Owczarek; Maciej Zaczek; Kinga Switała-Jeleń; Janusz Boratyński; Gryzelda Poźniak; Magdalena Maciejewska; Andrzej Górski
Journal:  BMC Microbiol       Date:  2009-01-20       Impact factor: 3.605

10.  Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.

Authors:  Maya Merabishvili; Jean-Paul Pirnay; Gilbert Verbeken; Nina Chanishvili; Marina Tediashvili; Nino Lashkhi; Thea Glonti; Victor Krylov; Jan Mast; Luc Van Parys; Rob Lavigne; Guido Volckaert; Wesley Mattheus; Gunther Verween; Peter De Corte; Thomas Rose; Serge Jennes; Martin Zizi; Daniel De Vos; Mario Vaneechoutte
Journal:  PLoS One       Date:  2009-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.